AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25149088 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-575 (3, 6, 9, 12, or 15 mg/kg) once weekly (QW)
Number of subjects: 35
Study 25149088 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-575 (25 or 35 mg/kg) every 3 weeks (Q3W)
Number of subjects: 35
Study 25149761 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidemic patients
Number of subjects: 0
Study 25149761 — intervention group
Group type: COMPARATOR
Intervention: Noncandidemic patients (ICU) and healthy controls
Number of subjects: 0
Study 25150172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node count ≥21
Number of subjects: 735
Study 25150172 — intervention group
Group type: COMPARATOR
Intervention: Lymph node count <10
Number of subjects: 735
Study 25150172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node count
Number of subjects: 735
Study 25150513 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate pain relief (IPR) defined as an average pain score of >4 out of 10 on BPI question 5.
Number of subjects: 1187
Study 25150513 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IPR
Number of subjects: 1187
Study 25150513 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between BPI average pain question and WOMAC pain subscale
Number of subjects: 1187
Study 25150798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily plus rituximab 375 mg/m² intravenously (IV) weekly during cycle 1, then once per cycle until cycle 6, followed by continuous daily single-agent ibrutinib 420 mg until disease progression or until toxicities or complications precluded further treatment.
Number of subjects: 40
Study 25150798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab
Number of subjects: 40
Study 25151571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment
Number of subjects: 0
Study 25151571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25152984 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoter methylation of O6MGMT
Number of subjects: 53
Study 25152984 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoter methylation of DAPK
Number of subjects: 53
Study 25152984 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoter methylation of RASSF1A
Number of subjects: 53
Study 25152984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR)
Number of subjects: 53
Study 25154677 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 oocytes
Number of subjects: 20
Study 25154677 — intervention group
Group type: COMPARATOR
Intervention: D15 oocytes
Number of subjects: 20
Study 25154699 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 1 subjects with SNP rs7671167 (FAM13A)
Number of subjects: 794
Study 25154699 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema-predominant GOLD 1 cluster with SNPs rs7671167 (FAM13A) and rs161976 (BICD1)
Number of subjects: 794
Study 25154699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest FEV1% predicted cluster with SNPs rs1980057 (HHIP) and rs1051730 (CHRNA3)
Number of subjects: 794
Study 25154699 — intervention group
Group type: COMPARATOR
Intervention: Combinations of COPD genome-wide significant SNPs
Number of subjects: 794
Study 25154820 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T cells
Number of subjects: 15
Study 25155085 — intervention group
Group type: EXPERIMENTAL
Intervention: B-FAHF-2
Number of subjects: 25
Study 25155085 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 25
Study 25155085 — intervention group
Group type: COMPARATOR
Intervention: FAHF-2
Number of subjects: 25
Study 25155453 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 15
Study 25155588 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9669 100 mg BID
Number of subjects: 4
Study 25155588 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9669 500 mg QD
Number of subjects: 4
Study 25155588 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9669 500 mg BID
Number of subjects: 4
Study 25155604 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DTG once daily for 5 days
Number of subjects: 12
Study 25155604 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DTG once daily in combination with 700/100 mg FPV-RTV every 12 h for 10 days
Number of subjects: 12
Study 25156560 — intervention group
Group type: EXPERIMENTAL
Intervention: tetanus-diphtheria-acellular pertussis vaccine
Number of subjects: 0
Study 25157214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg administered at least 15 min after the last dose of rocuronium
Number of subjects: 0
Study 25159346 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical-7 (noninvasive hemoglobin monitoring)
Number of subjects: 88
Study 25159346 — intervention group
Group type: EXPERIMENTAL
Intervention: iSTAT (point-of-care testing)
Number of subjects: 88
Study 25159346 — intervention group
Group type: COMPARATOR
Intervention: CBC (standard laboratory complete blood count)
Number of subjects: 88
Study 25159833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stiffness (pulse wave velocity (PWV))
Number of subjects: 350
Study 25159833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output
Number of subjects: 350
Study 25159833 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume
Number of subjects: 350
Study 25159833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index
Number of subjects: 350
Study 25159833 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry, body composition, blood pressure, systemic inflammatory mediators, blood and urine biochemistry, physical and health outcomes
Number of subjects: 350
Study 25160814 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlas-based global shape analysis
Number of subjects: 1991
Study 25160980 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO) instrument used prospectively in 153 adult patients with EoE (72.5% male; median age, 38 years)
Number of subjects: 186
Study 25160980 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO score (range, 0-8.52)
Number of subjects: 186
Study 25160980 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active EoE based on endoscopic and histologic findings
Number of subjects: 186
Study 25160980 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation study with 120 patients with EoE (60.8% male; median age, 40.5 years)
Number of subjects: 186
Study 25162366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplantation (FMT) via nasogastric tube
Number of subjects: 4
Study 25162446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescent cholangiography (IFC) with concomitant fluorescent angiography
Number of subjects: 35
Study 25162446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent angiography
Number of subjects: 35
Study 25162465 — intervention group
Group type: EXPERIMENTAL
Intervention: sEH inhibitor (sEHI)
Number of subjects: 0
Study 25162465 — intervention group
Group type: EXPERIMENTAL
Intervention: LXA4 (100 nM)
Number of subjects: 0
Study 25162465 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-epi-LXA4 (100 nM)
Number of subjects: 0
Study 25162465 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-epi-LXA4
Number of subjects: 0
Study 25162465 — intervention group
Group type: COMPARATOR
Intervention: t-butyl-hydroperoxide
Number of subjects: 0
Study 25162522 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with binocular glaucoma (GP)
Number of subjects: 20
Study 25162522 — intervention group
Group type: COMPARATOR
Intervention: Healthy-sighted control subjects (GC)
Number of subjects: 20
Study 25162522 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who passed the task (GP)
Number of subjects: 20
Study 25162818 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 95
Study 25163590 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterols (PS) plus β-Cryptoxanthin (β-Cx)
Number of subjects: 19
Study 25163590 — intervention group
Group type: COMPARATOR
Intervention: Phytosterols (PS)
Number of subjects: 19
Study 25163595 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant IMRT (median dose 50 Gy, 26-55) followed by surgery and IOERT (10-12 Gy)
Number of subjects: 27
Study 25164021 — intervention group
Group type: EXPERIMENTAL
Intervention: PDC31 (1 mg/kg/h)
Number of subjects: 24
Study 25164021 — intervention group
Group type: EXPERIMENTAL
Intervention: PDC31 (0.01, 0.05, 0.15, 0.3, 0.5, 1 mg/kg/h)
Number of subjects: 24
Study 25164234 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m(2) intravenously on day 1, and irinotecan 80 mg/m(2) on days 1 and 8, of a 21-day cycle up to 15 cycles or until disease progressed.
Number of subjects: 9
Study 25164234 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and irinotecan combination treatment.
Number of subjects: 9
Study 25164437 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib-based 1st-line regimen
Number of subjects: 281
Study 25164560 — intervention group
Group type: EXPERIMENTAL
Intervention: M probe (LSM1)
Number of subjects: 868
Study 25164560 — intervention group
Group type: EXPERIMENTAL
Intervention: M probe re-evaluation by experienced operators (LSM2)
Number of subjects: 868
Study 25164560 — intervention group
Group type: EXPERIMENTAL
Intervention: XL probe (LSMXL)
Number of subjects: 868
Study 25164945 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy added to a standard heart failure regimen
Number of subjects: 12
Study 25165055 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGB (Swedish Adjustable Gastric Band)
Number of subjects: 29
Study 25165428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone administered every other day for up to fourteen days.
Number of subjects: 195
Study 25165428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 195
Study 25166023 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 30, 100, 200, or 400 mg once daily or 300 mg twice daily, or placebo
Number of subjects: 116
Study 25166023 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 116
Study 25166023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 25166484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride (HCL), 200 to 300 mg/d, twice-daily immediate-release
Number of subjects: 4
Study 25167069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Detoxification treatment for alcohol use disorder
Number of subjects: 164
Study 25167069 — intervention group
Group type: COMPARATOR
Intervention: Control: Not applicable
Number of subjects: 164
Study 25167204 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 56
Study 25167204 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding (FF)
Number of subjects: 56
Study 25167204 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF) for at least 1 year
Number of subjects: 56
Study 25167216 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFα therapy (adalimumab)
Number of subjects: 198
Study 25167216 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-6R therapy (tocilizumab)
Number of subjects: 198
Study 25168219 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-fludelone (KOS-1803)
Number of subjects: 0
Study 25168842 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 120
Study 25169593 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-shaped Medtronic bifurcation-dedicated stent (BDS)
Number of subjects: 45
Study 25169854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg over 40 min)
Number of subjects: 133
Study 25169950 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels
Number of subjects: 302
Study 25169950 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD2 score with copeptin
Number of subjects: 302
Study 25169950 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD3-I score with copeptin
Number of subjects: 302
Study 25169950 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reclassification based on copeptin
Number of subjects: 302
Study 25170013 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) and Dasatinib (70 mg daily)
Number of subjects: 35
Study 25170013 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 35
Study 25170123 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL1/ABL ≤10% at 3 months
Number of subjects: 40
Study 25170123 — intervention group
Group type: COMPARATOR
Intervention: Imatinib treatment with BCR-ABL1/ABL >10% at 3 months
Number of subjects: 40
Study 25170245 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAV/TIM-FC (travoprost 0.004%/timolol 0.5%) administered once daily at 8 pm for 4-6 weeks
Number of subjects: 49
Study 25170245 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAV/TIM-FC
Number of subjects: 49
Study 25171955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription opioid users
Number of subjects: 529
Study 25171955 — intervention group
Group type: COMPARATOR
Intervention: Heroin users
Number of subjects: 529
Study 25173047 — intervention group
Group type: EXPERIMENTAL
Intervention: EPHX2 287Gln variant
Number of subjects: 85
Study 25173047 — intervention group
Group type: EXPERIMENTAL
Intervention: EPHX2 Arg287Gln genotype
Number of subjects: 85
Study 25173047 — intervention group
Group type: COMPARATOR
Intervention: EPHX2 287Gln carriers
Number of subjects: 85
Study 25173047 — intervention group
Group type: EXPERIMENTAL
Intervention: Total EETs
Number of subjects: 85
Study 25173458 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus sorafenib (sorafenib at 400 mg/bid, TACE with lipiodol, 50 mg doxorubicin, and PVA particles repeated q6w)
Number of subjects: 43
Study 25173458 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus sorafenib
Number of subjects: 43
Study 25173754 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 728
Study 25174587 — intervention group
Group type: EXPERIMENTAL
Intervention: CD33-directed chimeric antigen receptor-modified T cells (CART-33)
Number of subjects: 1
Study 25174996 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine immediate release (IR)
Number of subjects: 1230
Study 25174996 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine extended release (XR)
Number of subjects: 1230
Study 25174996 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine IR and XR (combined analysis)
Number of subjects: 1230
Study 25175077 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries risk assessment (CRA) decision based on past caries experience in adult patients
Number of subjects: 189
Study 25175077 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries risk assessment (CRA) decision based on use of fluorides in adult patients
Number of subjects: 189
Study 25175077 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries risk assessment (CRA) decision based on oral hygiene in pediatric patients
Number of subjects: 189
Study 25175077 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries risk assessment (CRA) decision based on use of fluorides in pediatric patients
Number of subjects: 189
Study 25175512 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25175864 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 25175864 — intervention group
Group type: EXPERIMENTAL
Intervention: Innate immune pattern-recognition receptor TLR4
Number of subjects: 0
Study 25178675 — intervention group
Group type: EXPERIMENTAL
Intervention: Advagraf®-based immunosuppression
Number of subjects: 50
Study 25178675 — intervention group
Group type: COMPARATOR
Intervention: Control group (MELD-score ≤20)
Number of subjects: 50
Study 25178675 — intervention group
Group type: COMPARATOR
Intervention: Control group (MELD-score >20)
Number of subjects: 50
Study 25179289 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids (shared decision making tools)
Number of subjects: 775
Study 25179289 — intervention group
Group type: COMPARATOR
Intervention: Control (no decision aids)
Number of subjects: 775
Study 25179634 — intervention group
Group type: EXPERIMENTAL
Intervention: sSOAIC (standard selective ophthalmic artery infusion chemotherapy)
Number of subjects: 17
Study 25179634 — intervention group
Group type: EXPERIMENTAL
Intervention: bSOAIC (balloon-assisted selective ophthalmic artery infusion chemotherapy)
Number of subjects: 17
Study 25179634 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary balloon occlusion (TBO) of the external carotid artery (ECA)
Number of subjects: 17
Study 25179634 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil infusion into the OA and internal carotid artery
Number of subjects: 17
Study 25179634 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall procedure
Number of subjects: 17
Study 25180155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (JAK1/2 inhibitor)
Number of subjects: 1
Study 25180155 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 1
Study 25180584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quantity lipid-based nutrient supplements (HQ-LNS) with cash (€38/month)
Number of subjects: 5395
Study 25180584 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-quantity lipid-based nutrient supplements (MQ-LNS) with cash (€38/month)
Number of subjects: 5395
Study 25180584 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+) with cash (€38/month)
Number of subjects: 5395
Study 25180584 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+) with family food ration
Number of subjects: 5395
Study 25180584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quantity lipid-based nutrient supplements (HQ-LNS) only
Number of subjects: 5395
Study 25180584 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+) only
Number of subjects: 5395
Study 25180584 — intervention group
Group type: COMPARATOR
Intervention: Cash transfer only (€43/month)
Number of subjects: 5395
Study 25181387 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy for ovarian cancer
Number of subjects: 1
Study 25181608 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help weight loss program (12 brief sessions across 5 months)
Number of subjects: 50
Study 25182067 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health nurse-administered program in Prince Edward Island
Number of subjects: 2
Study 25182067 — intervention group
Group type: COMPARATOR
Intervention: Physician-administered program in Nova Scotia
Number of subjects: 2
Study 25183428 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential proximity to a major road
Number of subjects: 183
Study 25183428 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-weighted traffic density within 100 meters
Number of subjects: 183
Study 25183428 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-weighted traffic density within 200 meters
Number of subjects: 183
Study 25183991 — intervention group
Group type: EXPERIMENTAL
Intervention: 5En%-protein diet
Number of subjects: 70
Study 25183991 — intervention group
Group type: EXPERIMENTAL
Intervention: 15En%-protein diet
Number of subjects: 70
Study 25183991 — intervention group
Group type: EXPERIMENTAL
Intervention: 30En%-protein diet
Number of subjects: 70
Study 25183991 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-containing diets (15En% and 30En%)
Number of subjects: 70
Study 25185097 — intervention group
Group type: EXPERIMENTAL
Intervention: TH-302 plus doxorubicin induction treatment
Number of subjects: 91
Study 25185097 — intervention group
Group type: EXPERIMENTAL
Intervention: TH-302 maintenance therapy
Number of subjects: 91
Study 25185630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical management for fecal incontinence
Number of subjects: 0
Study 25185712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide at 120 mg/kg plus cyclosporine and prophylaxis
Number of subjects: 22
Study 25185712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide at 120 mg/kg
Number of subjects: 22
Study 25185778 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes care according to national guidelines (623 individuals)
Number of subjects: 1533
Study 25185778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial target-driven management (910 individuals)
Number of subjects: 1533
Study 25185797 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Lactococcus lactis
Number of subjects: 0
Study 25186534 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25186535 — intervention group
Group type: EXPERIMENTAL
Intervention: ADOA patients
Number of subjects: 43
Study 25186535 — intervention group
Group type: COMPARATOR
Intervention: Control group (mutation-free relatives)
Number of subjects: 43
Study 25186780 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy with adjunctive systemic antibiotics
Number of subjects: 97
Study 25186780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 97
Study 25187030 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a (63μg)
Number of subjects: 35
Study 25187030 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a (125μg)
Number of subjects: 35
Study 25187030 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 35
Study 25187030 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin levels
Number of subjects: 35
Study 25187030 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Number of subjects: 35
Study 25187694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib 0.3 mg
Number of subjects: 46
Study 25187881 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg QD
Number of subjects: 0
Study 25187881 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg QD
Number of subjects: 0
Study 25187881 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg BID
Number of subjects: 0
Study 25187881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25187919 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT or LAM
Number of subjects: 700